Clinical Reference Laboratory Drug Test Codes: Everything You Need to Know for Outsourcing

Last Updated: May 7, 2026 — Added: definitive CPT codes 80320-80377, HCPCS G0480-G0483 for Medicare, DOT/SAMHSA federal workplace drug testing framework, MRO, chain of custody, specimen types, updated LOINC examples, coding systems comparison table, expanded FAQ.

Key Takeaways

• Standardized drug test codes (CPT, LOINC, ICD-10-CM, HCPCS) ensure tests are accurately identified, billed, and transmitted across healthcare systems.
• CPT codes are divided into presumptive/screening (80305–80307) and definitive/confirmation (80320–80377) — with important payer-specific differences: Medicare requires HCPCS G0480–G0483 for definitive testing, not CPT 80320–80377.
• Federal workplace drug testing (DOT/SAMHSA) operates under a distinct framework — mandatory 5-panel urine testing with chain of custody, Medical Review Officer review, and SAMHSA Mandatory Guidelines.
• When outsourcing drug testing, providing exact CPT or LOINC codes in your lab request eliminates ambiguity and accelerates the quoting process.

Introduction: Why Drug Test Codes Are the Backbone of Laboratory Outsourcing

Toxicology and diagnostic testing require high precision — not just in the laboratory, but in the data exchange between facilities. For healthcare providers, employers, pain management practices, addiction treatment centers, and clinical research organizations (CROs) outsourcing drug testing work, clinical reference laboratory drug test codes are the operational backbone of the process. Understanding how to use these codes ensures accurate billing, reliable test identification, regulatory compliance, and smooth integration with third-party testing facilities.

The coding landscape for drug testing is more complex than many outsourcing organizations realize. Presumptive (screening) and definitive (confirmation) testing use different CPT code families. Medicare requires different HCPCS codes than commercial payers for definitive testing. Federal workplace testing under DOT/SAMHSA operates under its own regulatory framework with a chain of custody and Medical Review Officer requirements. And different specimen types (urine, oral fluid, hair, blood) have distinct coding pathways. This guide covers the complete drug test coding landscape for laboratory outsourcing professionals.

ContractLaboratory.com connects healthcare organizations, employers, pain management practices, and CROs with CLIA-certified clinical and medical testing laboratories for all forms of drug testing. See also our guide to STAT, urgent, and routine laboratory testing, toxicology and biocompatibility testing.

Drug Test Coding Systems: Quick Reference Comparison

Code system	Maintained by	Primary purpose	Used by	Drug testing examples
CPT	American Medical Association (AMA); updated annually	Medical procedure billing and documentation (US)	Physicians, hospitals, labs for commercial payer billing	80305/80306/80307 (presumptive); 80320–80377 (definitive). NOT used for Medicare definitive testing.
HCPCS Level II (G codes)	Centers for Medicare & Medicaid Services (CMS); updated annually	Medicare/Medicaid billing for services not covered by CPT	Clinical labs billing Medicare/Medicaid for definitive drug testing	G0480 (1–7 drug classes); G0481 (8–14); G0482 (15–21); G0483 (22+). Required instead of CPT for Medicare definitive drug testing.
LOINC	Physicians, hospitals, and labs for commercial payer billing	Electronic health data exchange and interoperability — transmitting what was tested and what the result means	LIS/EHR systems for data exchange; clinical decision support	19295-5 (Opiates in Urine, Screen); 3773-9 (Methadone in Urine, Screen); 4023-8 (Cocaine in Urine, Screen)
ICD-10-CM (US)	NCHS/CDC (diagnoses); updated annually (Oct 1)	Diagnosis coding — establishing medical necessity for the test	Physicians, facilities for diagnosis-based insurance claims	F11.20 (Opioid dependence); F12.20 (Cannabis dependence); Z79.899 (Long-term drug use, NOS)
SNOMED CT	SNOMED International; licensed for US use	Clinical terminology and semantic interoperability within EHRs	EHR clinical documentation; mapped to LOINC for laboratory results	Used in clinical documentation layers; often mapped to LOINC for laboratory reporting purposes

Why Standardized Coding Matters When Outsourcing Lab Work

1. Ensuring Accuracy and Standardization Across Facilities

A “drug panel” can mean completely different things depending on the facility — a 5-panel urine screen vs a 12-panel urine screen vs a 10-panel oral fluid screen vs a comprehensive pain management monitoring panel with individual drug class reporting. Standardized codes define the exact substances being screened, the detection limits required, the methodology (immunoassay vs. mass spectrometry), and whether results are qualitative (positive/negative) or quantitative (with specific concentration values). This prevents the reference lab from performing the wrong test, using an unapproved methodology, or generating results that don’t meet your regulatory or legal requirements.

2. LIS/EHR Data Integration

Modern healthcare relies on automated data exchange. Standardized codes allow the results generated by the reference lab’s LIS to map directly back into the originating facility’s EHR. LOINC codes provide the semantic bridge ensuring that a test result transmitted from a reference laboratory is correctly interpreted by the receiving system — regardless of which laboratory performed the test or which LIS software it runs. For tips on LIMS integration, see our guide to integrating LIMS with instruments and enterprise systems.

3. Streamlining the RFP and Quoting Process

When finding a contract laboratory to handle high-volume toxicology screening, submitting a request with vague terms — like “urine drug screen” — delays the quoting process and risks getting the wrong test. Providing the exact CPT or LOINC codes allows the laboratory to immediately confirm its capabilities, check equipment availability, and provide an accurate cost-per-test estimate.

CPT Codes for Drug Testing: Presumptive and Definitive

CPT codes for drug testing fall into two distinct families that reflect two distinct testing methodologies with fundamentally different purposes, sensitivities, and billing implications. The two-tier testing approach — presumptive screening followed by definitive confirmation for positives — is the standard clinical and workplace drug testing workflow.

Presumptive Drug Testing CPT Codes (80305–80307): Screening

Presumptive testing provides an initial qualitative (positive/negative) assessment of whether a drug or drug class is present above a defined cutoff threshold. These codes are used for immunoassay-based and enzyme-based screening methods that can rapidly process large volumes of samples, but cannot identify individual drugs within a class or distinguish structural isomers. All three codes cover any number of drug classes per date of service:

• 80305: Drug test(s), presumptive; qualitative; utilizing immunoassay, enzyme assay, or chromatographic method (e.g., dipstick, cup, card, device, or cartridge). Includes sample validity testing when performed. Per date of service. Typically used for point-of-care (POC) or low-complexity immunoassay screening at a physician’s office or clinic.
• 80306: Drug test(s), presumptive; qualitative; read by instrument-graded, single drug class method (e.g., immunoassay, enzyme assay, or chromatography). Includes sample validity testing when performed. Instrument-read results provide more objectivity than 80305 visual reads.
• 80307: Drug test(s), presumptive; qualitative; utilizing instrument chemistry analyzers (e.g., immunoassay, enzyme assay, TOF, DART, or chromatography). Includes sample validity testing. Used for automated analyzer platforms. The most commonly reported presumptive code for high-volume clinical reference laboratory screening.

Important billing rule: CPT guidelines limit each presumptive code to one unit per date of service — regardless of how many drug classes are screened. Reporting multiple units of 80307 for multiple drug classes (e.g., 12 units for a 12-class panel) will almost certainly trigger an audit and potential recoupment. One unit covers the entire panel for that date.

Definitive Drug Testing CPT Codes (80320–80377): Confirmation

Definitive testing uses complex chromatographic methods — typically Gas Chromatography-Mass Spectrometry (GC-MS) or Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) — that can identify individual drugs within a drug class and distinguish between structural isomers (e.g., distinguishing prescribed methamphetamine from illegally used methamphetamine; or specific opioid metabolites). Definitive testing provides quantitative concentrations, not just positive/negative results, and is required to verify and confirm presumptive positives for clinical and legal purposes.

The 80320–80377 range includes class-specific codes (one code per drug type), each reported as one unit per date of service regardless of the number of drugs within that class:

• 80320: Alcohols (ethanol, methanol, isopropanol)
• 80322 / 80323: Amphetamines — 1 or 2 / 3 or more
• 80346 / 80347: Benzodiazepines — 1 or 2 / 3 or more
• 80348: Buprenorphine
• 80349: Cannabinoids, natural (THC, THC-COOH)
• 80350 / 80351 / 80352: Cannabinoids, synthetic — 1 or 2 / 3–6 / 7 or more
• 80353: Cocaine (cocaine, benzoylecgonine, ecgonine methyl ester)
• 80354: Fentanyl and norfentanyl
• 80358: Methadone and metabolites
• 80361 / 80362 / 80363 / 80364: Opioids and opiate analogs — 1 or 2 / 3–4 / 5 or more; or specific opiates 1 or 2
• 80365: Oxycodone and oxymorphone
• 80375 / 80376 / 80377: Drug(s) or substance(s), definitive, qualitative or quantitative, not otherwise specified — 1–3 / 4–6 / 7 or more drugs. Used when no specific class code exists.

⚠ Critical Medicare/Medicaid billing distinction: CPT codes 80320–80377 are not recognized for Medicare reimbursement for definitive drug testing. Medicare requires HCPCS G0480–G0483 instead (see next section). Some commercial payers follow CMS guidance; verify payer-specific policies before billing. Using CPT codes for Medicare definitive drug testing results in claim denials.

HCPCS G Codes (G0480–G0483): Medicare/Medicaid Definitive Drug Testing

For Medicare and Medicaid, definitive drug testing is billed using HCPCS Level II G codes. These codes not only specify the number of drug classes but require a higher analytical standard than CPT 80320-80377: the G code methodology must include stable isotope or universally recognized internal standards in all samples, method-specific calibration, and matrix-matched quality control materials — requirements aligned with high-complexity mass spectrometry confirmation testing:

• G0480: Definitive drug testing, 1–7 drug classes (including metabolites if performed). Per date of service. Requires chromatographic methods that can identify individual drugs and distinguish structural isomers.
• G0481: Definitive drug testing, 8–14 drug classes. Per date of service.
• G0482: Definitive drug testing, 15–21 drug classes. Per date of service.
• G0483: Definitive drug testing, 22 or more drug classes. Per date of service.

Only one G code may be reported per date of service. The correct code is selected based on the total number of definitive drug classes tested that day. Labs billing Medicare for comprehensive pain management monitoring panels — which may include 10–20+ individual definitive drug assays — must count the total drug classes tested and select the corresponding G code.

LOINC Codes for Drug Testing

LOINC codes serve as the universal standard for identifying medical laboratory observations in electronic data exchange. While CPT codes govern billing, LOINC codes govern data transmission — ensuring that a test result generated by a reference laboratory in one system is correctly identified and interpreted when it arrives in the ordering facility’s EHR. LOINC codes specify: the component (what is being measured); the property (presence, concentration, ratio); the time aspect (point-in-time vs. over duration); the system (specimen type: urine, serum, oral fluid, hair); the scale (quantitative, ordinal, nominal); and the method.

The structure of a LOINC code for drug testing provides more granular information than a CPT code — capturing specimen type, methodology, and whether the result is a screen (immunoassay) or a confirmed result (chromatographic). Examples of drug testing LOINC codes:

• 19295-5: Opiates [Presence] in Urine by Screen method (immunoassay-based presumptive)
• 3773-9: Methadone [Presence] in Urine by Screen method
• 4023-8: Cocaine [Presence] in Urine by Screen method
• 14316-6: Cannabinoids [Presence] in Urine by Screen method
• 19295-5 vs 3433-0: The same analyte (opiates) has different LOINC codes for screen (immunoassay, qualitative) vs confirmation (chromatographic, quantitative) methods — reflecting that LOINC distinguishes methodology in ways CPT does not

When outsourcing drug testing to a reference laboratory, confirming that the reference lab’s LIS can generate LOINC-coded results compatible with your EHR’s receiving interface is essential for automated result posting. Mismatched or absent LOINC codes require manual result entry — increasing transcription error risk and slowing result availability.

ICD-10-CM Diagnosis Codes: Establishing Medical Necessity

While CPT and LOINC codes define and transmit the test, ICD-10-CM diagnosis codes define the clinical reason for ordering the test. Insurance payers require a valid ICD-10-CM diagnosis code to establish medical necessity when billing for drug testing. Without appropriate diagnosis codes, claims may be denied even if the CPT codes are correct.

⚠ Important US clarification: As of May 2026, the United States continues to use ICD-10-CM for diagnosis coding. The US has NOT adopted ICD-11. WHO ICD-11 took global effect on January 1, 2022, and ICD-11 represents an important future direction — but the US currently remains in the exploratory phase of ICD-11 adoption. No CMS implementation date has been established. The National Committee on Vital and Health Statistics (NCVHS) established an ICD-11 workgroup in 2023 to develop recommendations for HHS, but no rulemaking has been initiated. The US likely uses ICD-10-CM for many years. Always use current ICD-10-CM codes for US billing — do not use ICD-11 codes for US insurance submissions.

Common ICD-10-CM codes used to justify drug testing:

• F11.20: Opioid dependence, uncomplicated — used for pain management and patient monitoring
• F12.20: Cannabis dependence, uncomplicated
• F14.20: Cocaine dependence, uncomplicated
• F19.10: Other psychoactive substance abuse, uncomplicated — covers polysubstance abuse monitoring
• Z79.891: Long-term (current) use of opiate analgesic — the most commonly used ICD-10-CM code for routine opioid therapy monitoring; not a dependence or abuse code
• Z02.83: Encounter for blood-alcohol and blood-drug test — for employment, pre-employment, or legal drug screening contexts
• T40.1X1A – T40.9X4A: Poisoning by narcotics and psychodysleptics, various agents — for emergency/acute drug exposure contexts

ICD-10-CM codes are updated annually, effective October 1 each fiscal year. Code additions, revisions, and deletions require annual review of the CMS/NCHS ICD-10-CM code updates. ICD-10-CM coding guidelines are maintained by the four cooperating parties: AHA, AHIMA, CMS, and NCHS.

Federal Workplace Drug Testing: DOT/SAMHSA Framework

A major commercial drug testing market distinct from clinical toxicology is federally mandated workplace drug testing under the Department of Transportation (DOT) and the Substance Abuse and Mental Health Services Administration (SAMHSA) Mandatory Guidelines. Employers who outsource federally regulated drug testing must understand how this framework differs from clinical drug testing.

DOT 5-Panel Drug Test

DOT regulations (49 CFR Part 40) mandate a specific 5-panel urine drug test for safety-sensitive transportation employees — commercial truck and bus drivers, pilots, railroad workers, pipeline operators, transit workers, and maritime personnel. The DOT 5-panel covers:

• Marijuana metabolites (THC-COOH): Screening cutoff 50 ng/mL; confirmation 15 ng/mL by GC-MS/LC-MS/MS
• Cocaine metabolites (benzoylecgonine): Screening cutoff 150 ng/mL; confirmation 100 ng/mL
• Amphetamines (amphetamine, methamphetamine, MDMA, MDA): Screening cutoff 500 ng/mL; confirmation 250 ng/mL each
• Opioids (codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, oxymorphone): Screening cutoff varies by drug; confirmation per SAMHSA guidelines
• Phencyclidine (PCP): Screening cutoff 25 ng/mL; confirmation 25 ng/mL

The laboratory performing DOT-regulated testing must be certified by SAMHSA’s National Laboratory Certification Program (NLCP). Standard CPT billing codes are not used in the DOT regulatory framework — DOT testing generates a separate chain of custody documentation and reporting distinct from clinical laboratory billing.

Chain of Custody and Medical Review Officer (MRO)

Two operational concepts are essential for regulated drug testing that clinical laboratory billing professionals must understand:

• Chain of Custody (COC): The documented, unbroken record of specimen handling from collection through laboratory analysis to final report. DOT requires the Federal Drug Testing Custody and Control Form (CCF). A broken chain of custody — any gap in documentation, improper collection, or specimen handling that compromises the specimen’s integrity and traceability — makes a positive drug test result legally indefensible. For employment, legal, and DOT testing, COC documentation is as operationally important as the test result itself.
• Medical Review Officer (MRO): A licensed physician with specific MRO training and certification who receives all laboratory-confirmed positive, adulterated, substituted, or invalid DOT drug test results. The MRO interviews the donor to determine if there is a legitimate medical explanation for a positive result (e.g., a confirmed opioid positive from a lawful prescription). The MRO issues the final verified result (positive, negative, cancelled, or test not performed) to the employer. MRO review is mandatory for all DOT-regulated drug tests and is increasingly used in non-DOT-regulated testing programs for added legal defensibility.

Specimen Types and Coding Implications

The article’s original focus on urine testing captures the most common specimen type — but clinical reference laboratories increasingly test multiple specimen types with different detection windows, clinical applications, and coding requirements:

• Urine (most common): Standard for DOT, most clinical, and workplace testing. Detection windows: marijuana 3–30+ days; cocaine 2–4 days; opioids 2–4 days. Vulnerable to adulteration, substitution, and dilution — specimen validity testing (creatinine, pH, specific gravity, oxidants) is standard. CPT codes 80305-80307 (presumptive) and 80320-80377/G0480-G0483 (definitive) apply.
• Oral fluid (buccal/mouth swab): Federally approved for DOT testing since January 2023. Shorter detection window (hours to 24–48 hours for most drugs) — better reflects recent use/impairment. More resistant to adulteration than urine (collected under direct observation). Growing for employment and return-to-duty testing. Different LOINC system codes (oral fluid rather than urine) apply; CPT codes may differ by payer.
• Hair follicle: Longest detection window (approximately 90 days for a 3-cm proximal hair segment). Used for pre-employment and return-to-duty where a historical drug use pattern is relevant. Cannot detect very recent use (drugs take 5–7 days to appear in hair). Not currently approved for DOT federal testing. Different LOINC system identifier (hair) and CPT coding pathway than urine.
• Blood: Most closely reflects current impairment — very short detection windows. Used for DUI/DWI forensic investigations, hospital toxicology in suspected overdose or acute impairment, clinical pharmacology studies, and therapeutic drug monitoring. Specific blood CPT codes apply (e.g., 80320 for blood ethanol). The G codes also apply to blood specimens for definitive testing.

Best Practices for Managing Lab Codes When Outsourcing

• Leverage LIS technology: Ensure your LIS automatically updates its CPT, HCPCS, and LOINC coding databases. This prevents claim denials caused by obsolete codes — particularly important for the annual October 1 ICD-10-CM updates and annual January 1 CPT updates.
• Distinguish payer type before coding: Verify whether you are billing Medicare/Medicaid (requiring G0480–G0483 for definitive testing) or commercial payers (CPT 80320–80377 accepted). Applying CPT codes to Medicare definitive drug test claims results in automatic denials.
• Know your testing tier: Presumptive screening codes (80305–80307) cover entire panels for one unit per date of service. Definitive codes (80320–80377 or G0480–G0483) are billed per drug class. Do not mix up the two tiers in the same billing context.
• Conduct annual training: Billing departments and lab managers should review annual AMA CPT updates (January 1 effective), LOINC bi-annual updates, and ICD-10-CM annual updates (October 1 effective) from the AMA, Regenstrief Institute, and CMS/NCHS.
• Communicate with your reference lab: Before finalizing an outsourcing agreement, verify that the reference lab’s reporting structure supports the specific codes your organization requires — CPT vs HCPCS, urine vs oral fluid LOINC codes, and the specific drug class panels you need. If the lab requires CLIA certification for specific test types, confirm the lab holds the appropriate CLIA certificate level.

Finding the Right Reference Lab for Drug Testing

Finding a qualified reference lab equipped to handle your specific drug testing requirements — whether high-volume urine toxicology screening for a pain management practice, federally mandated DOT testing, oral fluid collection programs, or comprehensive confirmatory testing with MRO services — shouldn’t be a bottleneck in your operations. Providing exact CPT, HCPCS, or LOINC codes when submitting a lab outsourcing request eliminates ambiguity and dramatically accelerates the matching and quoting process.

ContractLaboratory.com connects healthcare organizations, employers, substance abuse treatment programs, and CROs with accredited clinical and medical testing laboratories certified for all levels and types of drug testing. Submit a testing request or contact our team for more information.

Frequently Asked Questions (FAQs)

Conclusion

Clinical reference laboratory drug test codes — CPT presumptive (80305–80307), CPT definitive (80320–80377), HCPCS G codes (G0480–G0483 for Medicare), LOINC (data exchange), and ICD-10-CM (medical necessity justification) — form the operational backbone of drug testing outsourcing. Understanding the distinction between the payer-specific requirements (CPT vs. HCPCS for Medicare), the two-tier testing paradigm (presumptive screening followed by definitive confirmation), and the specialized regulatory framework for federal workplace testing (DOT/SAMHSA with chain of custody and MRO review) is essential for healthcare organizations, employers, and reference laboratory professionals managing drug testing outsourcing programs. Keep all coding updated annually and verify payer-specific requirements before billing.

ContractLaboratory.com connects organizations requiring drug testing services with accredited CLIA-certified clinical and medical testing laboratories. Submit a testing request or contact our team.